EGFR and breast cancer: In HER2-positive breast cancer cells, proteasome inhibitors induce degradation of ErbB family proteins by triggering Hsp90 inhibition through a chaperone stress response, thereby confirming these proteins as bona fide Hsp90 clients [115].